EUVIMEDEUVIMED entdecken
Crossref

Hippocampal 5-HT4/6 Receptor Antagonists Normalize Dopaminergic Dysfunction in a Rodent Model of Alzheimer’s Disease

Nicole E Eassa, Stephanie M Perez iD, Olivia J Yang, Angela M Boley, Daniel J Lodge

ACS Chemical Neuroscience · 04.11.2026 · 17 (21) · 3517-3525

DOI: 10.1021/acschemneuro.6c00432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 17.09.2026. Verfasst von Nicole E Eassa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Center for Biomedical Neuroscience, UT San Antonio, San Antonio, Texas78229, United States. Hauptthemen laut MEDLINE: Alzheimer Disease, Hippocampus, Receptors, Serotonin, Dopamine. Die Arbeit nennt 80 Literaturangaben. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychosis affects approximately 4 million Americans with Alzheimer’s disease (AD), yet safe and effective pharmacological treatments remain limited. The clinical utility of traditional antipsychotics is constrained by an FDA black box warning regarding increased mortality in the elderly. A potential mechanistic driver for these symptoms is hyperactivity in the ventral hippocampus (vHipp), a feature common to both AD and psychosis that has been shown in preclinical models to induce dopamine system dysregulation. This study explores the hypothesis that such hippocampal dysfunction is facilitated by aberrant serotonergic signaling. Clinical and preclinical studies suggest that activation of two serotonin-responsive G-protein-coupled receptors (GPCRs), 5-HT4R and 5-HT6R, in the hippocampus contributes to symptoms of psychosis in AD. Although targeting these receptors could provide therapeutic benefits, their widespread expression throughout the brain raises concerns about whether systemic administration would yield selective effects specifically in the hippocampus. To investigate this, we microinfused the selective 5-HT4 receptor antagonist (SB-204070) or the 5-HT6 receptor antagonist (PRX-07034) directly into the vHipp of TgWKY-AD and WKY-WT rats. Intra-vHipp blockade of either receptor reversed the pathological elevation of ventral tegmental area (VTA) dopamine neuron population activity; notably, these effects were fully recapitulated following systemic administration. We further demonstrated that 5-HT4R and 5-HT6R mRNA expressions in the vHipp and nucleus accumbens (NAc) are preserved in 12-month-old TgWKY-AD rats, suggesting that these targets remain viable as the disease progresses. Together, these findings identify systemic 5-HT4R or 5-HT6R antagonism as a viable therapeutic strategy to attenuate hippocampal hyperactivity and restore dopaminergic homeostasis, offering a mechanistically grounded and potentially safer alternative for managing psychosis in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHippocampusReceptors, SerotoninDopamineSerotonin AntagonistsSerotonin 5-HT4 Receptor AntagonistsDopaminergic NeuronsAnimalsMaleDisease Models, AnimalRatsReceptors, Serotonin, 5-HT4PiperazinesMesolimbic SystemRats, Sprague-Dawley

Stichwörter der Autor:innen

5-HT4 receptor5-HT6 receptorAlzheimer’s diseasedopaminepsychosisventral hippocampus

Substanzen

serotonin 6 receptorReceptors, SerotoninDopamineSerotonin AntagonistsReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor AntagonistsPiperazines

Autor:innen und Institutionen

  • Department of Pharmacology and Center for Biomedical Neuroscience, UT San Antonio, San Antonio, Texas78229, United States.
  • Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, Texas78229, United States.

ORCID-Profile: Stephanie M Perez

Förderung

  • NIA NIH HHS
  • NIGMS NIH HHS
  • NINDS NIH HHS
  • U.S. Department of Veterans Affairs
  • NCATS NIH HHS
  • San Antonio Nathan Shock Center of Excellence Pilot Grant
  • National Center for Advancing Translational Sciences
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Eassa, N. E., Perez, S. M., Yang, O. J., Boley, A. M., & Lodge, D. J. (2026). Hippocampal 5-HT4/6 Receptor Antagonists Normalize Dopaminergic Dysfunction in a Rodent Model of Alzheimer’s Disease. ACS Chemical Neuroscience, 17(21), 3517-3525. https://doi.org/10.1021/acschemneuro.6c00432

Vancouver

Eassa NE, Perez SM, Yang OJ, Boley AM, Lodge DJ. Hippocampal 5-HT4/6 Receptor Antagonists Normalize Dopaminergic Dysfunction in a Rodent Model of Alzheimer’s Disease. ACS Chemical Neuroscience. 2026;17(21):3517-3525. doi:10.1021/acschemneuro.6c00432

BibTeX
@article{Eassa2026,
  author = {Eassa, Nicole E and Perez, Stephanie M and Yang, Olivia J and Boley, Angela M and Lodge, Daniel J},
  title = {Hippocampal 5-HT4/6 Receptor Antagonists Normalize Dopaminergic Dysfunction in a Rodent Model of Alzheimer’s Disease},
  journal = {ACS Chemical Neuroscience},
  year = {2026},
  volume = {17},
  number = {21},
  pages = {3517--3525},
  doi = {10.1021/acschemneuro.6c00432}
}
Kostenlos starten →